



PRESS RELEASE

Voluntary Tender Offer launched by AGC Inc. on all ordinary shares of MolMed: the Board of Directors approves the Issuer's notice.

Milan (Italy), May 29th 2020 – The Board of Directors of MolMed S.p.A. (MLMD.MI) (the “**Issuer**”), met today under the chairmanship of Dr. Carlo Incerti, unanimously approved the Issuer’s statement (the “**Issuer’s Statement**”) prepared pursuant to article 103, paragraph 3, of Legislative Decree no. 58/1998 (the “**TUF**”) and Article 39 of Consob Regulation no. 11971/1999 in relation to the voluntary tender offer on all ordinary shares of the Issuer (the “**Offer**”) launched by AGC Inc. (“**AGC**”) pursuant to articles 102 of the TUF.

The Board of Directors has expressed its assessments regarding the Offer and in particular considered fair, from a financial point of view, the considerations of the Offers equal to Euro 0.518 for each ordinary share.

For the purposes of the above assessment, the Board of Directors has acknowledged (i) the terms and conditions of the Offer described in the related offer document approved by Consob today (the “**Offer Document**”), and (ii) the opinion issued by the independent financial advisor Centerview Partners UK LLP appointed by the Board of Directors itself.

For a full explanation of the assessments made by the Board of Directors on the Offer and on the fairness of the related considerations, please refer to the Issuer’s Statement (accompanied by the opinion issued by the above said independent advisor), which has been published today together with the Offer Document in accordance with the modalities provided for by current legislation.

About MolMed

MolMed S.p.A. is a clinical stage biotech company focused on research, development, manufacturing and clinical validation of innovative therapies. MolMed is the first company in Europe to have obtained the GMP manufacturing authorization for cell & gene therapies ex vivo for its proprietary products as well as for third parties and/or in partnership (Strimvelis, an Orchard gene therapy for the ADA-SCID). With reference to GMP development and manufacturing activities for third parties, MolMed signed numerous partnership agreements with leading European and US companies. MolMed’s is also developing its CAR-T CD44v6, which in March 2019 received the authorization to start human clinical trials in onco-hematologic indications (AML and MM), following an extensive pre-clinical phase. MolMed, founded in 1996 as an academic spin-off of the San Raffaele Scientific Institute, is listed on the main market (MTA) of the Milan stock exchange managed by Borsa Italiana since March 2008. MolMed is headquartered and based in Milan, at the San Raffaele Biotechnology Department (DIBIT) and has an operating unit at OpenZone in Bresso. For more information please visit www.molmed.com.

For further information:

MolMed S.p.A.

Investor Relations & Communication Department

MolMed S.p.A.

+39 02 21277.205

investor.relations@molmed.com

Tommasina Cazzato

Press Office

Community Group

+39 345 7357751

tommasina.cazzato@communitygroup.it